中國(guó)藥科大學(xué)

劉建平,1982年畢業(yè)于中國(guó)藥科大學(xué)藥學(xué)專業(yè)，現(xiàn)為中國(guó)藥科大學(xué)藥劑研究所所長(zhǎng)、藥劑教研室副主任，藥劑學(xué)博士、教授、博士生導(dǎo)師。1999年赴新西蘭Otago大學(xué)藥學(xué)院進(jìn)修。

兼任國(guó)家食品藥品監(jiān)督管理局保健品審評(píng)專家、農(nóng)業(yè)部獸藥審評(píng)專家、江蘇省藥劑專業(yè)委員會(huì)副主任、江蘇省藥品保健品制劑審評(píng)專家、江蘇省九三學(xué)社醫(yī)藥委員會(huì)委員等職。

研究方向：生物功能性藥物載體，緩控釋制劑、經(jīng)皮給藥系統(tǒng)、中藥新劑型

主要研究?jī)?nèi)容和成果：利用血漿高密度脂蛋白逆轉(zhuǎn)運(yùn)膽固醇，具有抗動(dòng)脈粥樣硬化的性質(zhì)和作用，重組高密度脂蛋白載藥系統(tǒng)，達(dá)到載體與藥物的協(xié)同治療作用，獲2項(xiàng)國(guó)家自然科學(xué)基金項(xiàng)目資助；針對(duì)中藥多成分體內(nèi)過程差異較大，不利于發(fā)揮協(xié)同作用的問題，對(duì)中藥多成分體內(nèi)過程進(jìn)行藥動(dòng)學(xué)與藥效學(xué)的二次調(diào)控與改造，獲1項(xiàng)國(guó)家自然科學(xué)基金項(xiàng)目資助。主持科技部“十一五”重大專項(xiàng)、國(guó)家中醫(yī)藥管理局項(xiàng)目、江蘇省“六大人才”高峰項(xiàng)目、江蘇省自然科學(xué)基金、江蘇省社會(huì)發(fā)展基金等項(xiàng)目項(xiàng)目，負(fù)責(zé)或參與科技部“十五”國(guó)家科技攻關(guān)、“十一五”國(guó)家科技支撐計(jì)劃、新西蘭國(guó)際合作項(xiàng)目、江蘇省高新技術(shù)招標(biāo)項(xiàng)目、江蘇省科技基礎(chǔ)設(shè)施建設(shè)計(jì)劃-科技公共服務(wù)平臺(tái)項(xiàng)目、江蘇省中醫(yī)藥管理局項(xiàng)目以及企業(yè)合作開發(fā)項(xiàng)目等共25項(xiàng)。

通過江蘇省科技廳成果鑒定三項(xiàng)，獲2004年南京市科技進(jìn)步獎(jiǎng)三等獎(jiǎng)、2011國(guó)家人口和計(jì)生委優(yōu)秀科技成果一等獎(jiǎng)，申請(qǐng)發(fā)明專利27項(xiàng)，已授權(quán)9項(xiàng)。發(fā)表論文129篇（其中SCI42篇、EI收載2篇）。

近3年發(fā)表的代表性論文（以下均為通訊作者）

1.Post-insertion of poloxamer 188 strengthened liposomal membrane and reduced drug irritancy and in vivo precipitation, superior to PEGylation [J]. Journal of Controlled Release, 2015, 23(10): 161-169.(SCI，7.705)

2.Suppression of Remodeling Behaviors with Arachidonic Acid Modification for Enhanced in vivo Antiatherogenic Efficacies of Lovastatin-loaded Discoidal Recombinant High Density Lipoprotein[J]. Pharmaceutical Research, Published online：04 June 2015.(SCI，3.952)

3.Tanshinone IIA loaded pellets developed for angina chronotherapy: Deconvolution-based formulation design and optimization, pharmacokinetic and pharmacodynamic evaluation[J]. European Journal of Pharmaceutical Sciences, 2015, 76(2015): 156–164.(SCI，3.35)

4.Strategies to Maximize Liposomal Drug Loading for a Poorly Water-soluble Anticancer Drug [J]. Pharmaceutical research, 2015, 32(4): 1451-1461. (SCI，3.952)

5.Physicochemical characterization of asulacrine towards the development of an anticancer liposomal formulation via active drug loading: Stability, solubility, lipophilicity and ionization. International Journal of Pharmaceutics, 2014, 473 (1–2), 528–535. (SCI，3.785)

6.Hyaluronic acid-decorated reconstitude high density lipoprotein targeting atherosclerotic lesion [J]. Biomaterials, 2014, 35(27): 8002–8014. (SCI，8.312)

7.Arachidonic Acid-modified Lovastatin Discoidal Reconstituted High Density Lipoprotein Markedly Decrease the Drug Leakage during the Remodeling Behaviors Induced by Lecithin Cholesterol  Acyltransferase. Pharmaceutical Research, 2014, 31(7): 1689-1709. ( SCI， 3.952)

8.Pharmacokinetics and atherosclerotic lesions targeting effects of tanshinone IIA discoidal and spherical biomimetic high density lipoproteins, Biomaterials, 2013, 34(1):306-319. (SCI， 7.604)

9.Bioavailability and foam cells permeability enhancement of Salvianolic acid B pellets based on drug–phospholipids complex technique. European journal of pharmaceutics and biopharmaceutics, 2013,83(1):76-86. (SCI，3.826)

10.Release Behavior of Tanshinone IIA Sustained-Release Pellets Based on Crack Formation Theory. Journal of pharmaceutical sciences, 2012,101(8):2811-2820. (SCI，3.055)

11.Preparation, Characterizations, and In Vitro Metabolic Processes of Paclitaxel-Loaded Discoidal Recombinant High-Density Lipoproteins. Journal of pharmaceutical science, 2012,101(8):2900-2908. (SCI，3.055)

12.Novel Tanshinone II A ternary solid dispersion pellets prepared by a single-step technique: in vitro and in vivo evaluation. European Journal of Pharmaceutics and Biopharmaceutics, 2012,80:426-432. (SCI，4.269)

聯(lián)系方式：025-83271293（O）,13951923397,jianpingliu1293@163.com